Biogen Idec (NASDAQ:BIIB)

Top Analyst Upgrades and Downgrades: Biogen, Carbonite, Celgene, Emerson Electric, Kinder Morgan, Netflix, UnitedHealth and Many More

Stocks hit a new high on Monday, and they were indicated to open slightly higher on Tuesday. The Dow is now knocking on 23,000's door, and this bull market is ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, September 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AMD, Biogen, Capital One, Intuit, Jinko Solar, Micron, Albermarle, Alnylam and More

Stocks were indicated to open marginally lower on Thursday. This is on the heels of Wednesday's confirmation by Janet Yellen that the Federal Reserve would start selling down its $4.5 ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Biogen, Electronic Arts, Gap, Intuit, J&J, 3M, Intercept, AutoZone and More

Stocks were looking for direction on Wednesday, but this after the major indexes have all hit fresh all-time highs. The one trend that has dominated this bull market is that ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, August 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Merrill Lynch Top Health Care Stock Picks for September: Focus on Large Cap Biotech

Merrill Lynch recently released its September RIC Report, noting key strategy views and showing many sector views. One such view from the firm was that health care stocks are currently ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The short interest data are out for the most recent settlement date, August 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Major Biotechs Send Short Sellers Running for Cover

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Pfizer, Royal Caribbean, Shopify, Under Armour, Walmart and More

Stocks were indicated to open higher yet again on Wednesday for all-time highs on the Dow and S&P 500, with the Dow challenging 22,000 for the first time ever after ...
Read Full Story »

Analyst Has Top Biotech Stocks to Buy as Sector Stays Red Hot

After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. While nowhere near the ...
Read Full Story »

Short Sellers Run for Cover From Major Biotech Stocks

The short interest data are out for the most recent settlement date, July 14. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, June 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Meet Jefferies Top 12 Picks in the Roaring Biotech Industry

The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has ...
Read Full Story »